C2RS34 fundamentals
An in-depth look to CRISPR THERADRN operating, investing, and financing activities
C2RS34 free cash flow for Q1 24 is 547.89 M BRL. For 2023, C2RS34 free cash flow was -1.31 B BRL and operating cash flow was -1.27 B BRL.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: BRL
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM